The Pulse of the Oncologist: Listening to What Matters Most

Advancing Endometrial Cancer Care with Molecular Profiling

In this compelling episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by innovators Dr. Angeles Alvarez Secord and Dr. Aine Clements to discuss high-impact data on endometrial cancer, focusing on the landmark GOG258 trial through the lens of modern molecular classification. The trio explores how integrating single-gene testing for markers such as POL-E, mismatch repair, and p53 mutations is redefining “high risk,” shifting treatment strategies, and offering new hope for patients with advanced endometrial cancer. Hear first-hand about the years-long research journey, the challenges of trial design, and what practice-changing insights these findings bring to clinicians and patients, particularly regarding treatment de-escalation, prognosis, and precision oncology. Tune in now to learn how GOG258’s molecular analysis is shaping the future of personalized medicine in uterine cancer care. Follow Us * LinkedIn @labcorp [https://www.linkedin.com/company/labcorp/] * X @labcorp [https://x.com/LabCorp] * Facebook @labcorp [https://www.facebook.com/Labcorp/] * Instagram @labcorp [https://www.instagram.com/labcorp/] * YouTube @LabCorpMedia [https://www.youtube.com/labcorpmedia] Presented by Labcorp Oncology www.oncology.labcorp.com [http://www.oncology.labcorp.com] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

The Pulse of the Oncologist: Listening to What Matters Most

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs welcomes Dr. Brian Caveney, Labcorp’s Chief Medical and Scientific Officer, to unpack findings from the Pulse of the Oncologist report—a nationwide survey capturing the real-world perspectives of 152 oncologists across practice settings. Together, Dr. Rebecca Previs and Brian Caveney dive into the pressing issues that shape oncology care today: the rising complexity of cancer treatment, the critical importance of diagnostic turnaround time, and how digital innovation can ease clinical workflows and reduce friction. They discuss why interpretive clarity in lab reports matters more than ever and spotlight the game-changing role of molecular residual disease (MRD) testing in monitoring and guiding patient care. The conversation highlights practical solutions for improving access to advanced diagnostics, the emotional and financial burdens patients and providers face, and how health systems, labs, and payers must partner to drive equity and innovation. Ready to hear what oncologists really want and what’s next for cancer care? Tune in now for essential insights that will reshape your view of the future of oncology. Follow Us * LinkedIn @labcorp [https://www.linkedin.com/company/labcorp/] * X @labcorp [https://x.com/LabCorp] * Facebook @labcorp [https://www.facebook.com/Labcorp/] * Instagram @labcorp [https://www.instagram.com/labcorp/] * YouTube @LabCorpMedia [https://www.youtube.com/labcorpmedia] Presented by Labcorp Oncology www.oncology.labcorp.com [http://www.oncology.labcorp.com] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

Navigating the Future of CDXs in Oncology

How are companion diagnostics (CDXs) transforming the landscape of precision oncology? In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs welcomes CDX expert Dawn McHugh, Director of Precision Oncology CDx at Labcorp, for a deep dive into the evolving world of companion diagnostics. You’ll learn what defines a true CDX, how it differs from other biomarker tests, and why integrating it with targeted therapies is essential for matching the right patient to the right treatment. Dawn McHugh guides us through real-world examples—from HER2 and EGFR to the latest in liquid biopsy—explaining how these diagnostics are expanding access, shaping new therapies, and accelerating the pace of cancer innovation. The conversation explores development timelines, regulatory hurdles, the value of early collaboration, and emerging technologies like AI and decentralized NGS. Whether you’re an oncologist, researcher, or pharma partner, this episode delivers actionable insights on the present and future impact of CDXs in oncology care. Tune in for a dynamic, forward-looking discussion and gain a new perspective on the science fueling tomorrow’s breakthroughs. Follow Us * LinkedIn @labcorp [https://www.linkedin.com/company/labcorp/] * X @labcorp [https://x.com/LabCorp] * Facebook @labcorp [https://www.facebook.com/Labcorp/] * Instagram @labcorp [https://www.instagram.com/labcorp/] * YouTube @LabCorpMedia [https://www.youtube.com/labcorpmedia] Presented by Labcorp Oncology www.oncology.labcorp.com [http://www.oncology.labcorp.com] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

FFPE: The Workhorse Behind NGS Testing

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by Dr. Kyle Strickland, Director of Medical Affairs and pathologist at Labcorp, and Dr. Erin Newburn, field application scientist and genomicist, for a deep dive into tissue stewardship and the pivotal role of FFPE specimens in precision oncology. Together, the team demystifies how formalin-fixed paraffin-embedded (FFPE) samples have become the gold standard in both clinical and research settings for biomarker testing. They discuss the science behind tissue preservation, compare FFPE to fresh and frozen samples, and reveal the unique challenges these specimens present for next-generation sequencing. Explore the crucial pre-analytical factors influencing sample quality and how emerging innovations are pushing the boundaries of what’s possible in cancer diagnostics, clinical trials, and translational research. Whether you’re a clinician seeking to optimize patient care, a researcher navigating limited samples, or simply curious about the future of precision medicine, this conversation provides practical insights and actionable tips directly from the experts transforming the field. Tune in now to discover how the workhorse of pathology is powering a new era in oncology. Follow Us * LinkedIn @labcorp [https://www.linkedin.com/company/labcorp/] * X @labcorp [https://x.com/LabCorp] * Facebook @labcorp [https://www.facebook.com/Labcorp/] * Instagram @labcorp [https://www.instagram.com/labcorp/] * YouTube @LabCorpMedia [https://www.youtube.com/labcorpmedia] Presented by Labcorp Oncology www.oncology.labcorp.com [http://www.oncology.labcorp.com] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

ctDNA Breakthroughs in Mesothelioma Care

In this insightful episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with Dr. Mark Sausen, Labcorp's Head of Technology and Innovation, to break down a cutting-edge Phase II clinical trial exploring perioperative immunotherapy for resectable diffuse pleural mesothelioma, a rare and aggressive cancer. Hear firsthand how the introduction of immune checkpoint blockade and an ultrasensitive tumor-informed ctDNA platform offers new hope for tracking and treating patients when imaging falls short. Dr. Sausen shares the technological breakthroughs behind molecular residual disease detection, the impact of ctDNA on progression-free survival, and practical challenges in implementing these assays across multicenter studies. Whether you’re a clinician, researcher, or patient advocate, discover how molecular monitoring is changing the game for mesothelioma and rare cancers alike. Tune in now to reimagine the future of oncology care. Follow Us * LinkedIn @labcorp [https://www.linkedin.com/company/labcorp/] * X @labcorp [https://x.com/LabCorp] * Facebook @labcorp [https://www.facebook.com/Labcorp/] * Instagram @labcorp [https://www.instagram.com/labcorp/] * YouTube @LabCorpMedia [https://www.youtube.com/labcorpmedia] Presented by Labcorp Oncology www.oncology.labcorp.com [http://www.oncology.labcorp.com] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.